title: The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients.
abstract: Ninety-seven patients randomized to receive (45 patients) or not to receive (52 patients) intravenous cytomegalovirus immune globulin before and after allogeneic marrow transplantation were evaluated retrospectively for the occurrence of bacterial and fungal septicemia in the first 100 days post-transplant. In a proportional hazards regression test, infection prevention regimens, immunoglobulin administration, age and occurrence of acute graft-versus-host disease were tested simultaneously for the occurrence of septicemia in the pre- and post-engraftment period. Of these factors, only patients receiving immunoglobulin had significantly fewer episodes of septicemia following engraftment with 11 (26%) patients in the globulin group having 14 episodes compared to 22 (42%) patients in the control group having 27 episodes (p = 0.039). None of the patients experienced complications with the immunoglobulin infusions. These results suggest that the administration of intravenous immunoglobulin may be a practical and effective method to decrease the incidence of septicemia following marrow transplantation.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
authors.forename: F B
authors.initials: FB
authors.lastname: Petersen
authors.forename: R A
authors.initials: RA
authors.lastname: Bowden
authors.forename: M
authors.initials: M
authors.lastname: Thornquist
authors.forename: J D
authors.initials: JD
authors.lastname: Meyers
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: G W
authors.initials: GW
authors.lastname: Counts
authors.forename: N
authors.initials: N
authors.lastname: Nelson
authors.forename: B A
authors.initials: BA
authors.lastname: Newton
authors.forename: K M
authors.initials: KM
authors.lastname: Sullivan
authors.forename: J
authors.initials: J
authors.lastname: McIver
mesh_terms: D016026:Bone Marrow Transplantation; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects*; D007938:Leukemia / Q000628:therapy; D009894:Opportunistic Infections / Q000517:prevention & control; D012189:Retrospective Studies; D018805:Sepsis / Q000209:etiology* / Q000382:microbiology